{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T19:09:53Z","timestamp":1772996993933,"version":"3.50.1"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Melanoma hepatic metastases demonstrate limited responsiveness to conventional systemic immune checkpoint blockade therapy, primarily attributed to the hepatic microenvironment's immunosuppressive characteristics. To our knowledge, this is the first reported case describing selective hepatic arterial infusion of pembrolizumab immediately followed by transarterial chemoembolization (TACE) for liver\u2010dominant melanoma metastases after progression on systemic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>This case report describes an alternative therapeutic strategy employed for a 61\u2010year\u2010old female patient with hepatic metastases secondary to chemotherapy\u2010refractory uveal melanoma. Therapeutic intervention consisted of selective hepatic arterial pembrolizumab infusion immediately succeeded by TACE utilizing carboplatin, mitomycin, and idarubicin combined with lipiodol emulsion. Treatment cycles were administered at eight\u2010week intervals for two sessions. Radiological assessment 3\u2009months post\u2010treatment demonstrated a complete response with absence of detectable hepatic malignancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This clinical experience represents the initial documentation of sequential intraarterial pembrolizumab followed by TACE in chemotherapy\u2010resistant melanoma hepatic metastases. While a complete radiologic response was observed, conclusions regarding efficacy cannot be drawn from a single case. This approach appears feasible and warrants further study in well\u2010designed clinical investigations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cnr2.70500","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T13:37:29Z","timestamp":1771335449000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transarterial Infusion of Pembrolizumab Plus\n                    <scp>TACE<\/scp>\n                    for Liver Metastases of Melanoma"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9993-3801","authenticated-orcid":false,"given":"Shahram","family":"Akhlaghpoor","sequence":"first","affiliation":[{"name":"Department of Interventional Radiology Pardis Noor Medical Imaging and Cancer Center  Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7395-1320","authenticated-orcid":false,"given":"Hamidreza","family":"Rouientan","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology Pardis Noor Medical Imaging and Cancer Center  Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2702072"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znaf130"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-55675-5"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12041027"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13111836"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_75_20"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02566-z"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000436"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001097"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003311"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2022.10.011"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2019.11.002"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2017.04.025"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2024.08.005"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.11081489"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00748-2"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2691"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0325"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1541105"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01235-0"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2277"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2014.11.037"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70500","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cnr2.70500","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T16:16:25Z","timestamp":1772986585000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.70500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/cnr2.70500"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.70500","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70500"}}